VLTR-559 / Valitor - LARVOL DELTA

Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology’s Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire) - "The lead development candidate, VLTR-559, is a long-acting anti-VEGF biologic designed to enable twice-yearly dosing for the treatment of wet age-related macular degeneration (AMD) for improved long-term outcomes and reduced clinical treatment costs and burden: Engineered to both extend the intravitreal half-life and increase the potency of anti-VEGF therapy; Could enable a reduced twice-yearly dosing frequency, versus eight to twelve weeks for current standard-of-care anti-VEGFs; Potent VEGF inhibition and high drug concentration found in target tissues in vivo; Preclinical safety profile consistent with marketed anti-VEGF biologics; Advancing through IND-enabling activities with a Phase 1 study expected to begin in 2026."

New P1 trial • Preclinical • Wet Age-related Macular Degeneration